Approval · Notice of Compliance 14609 · 2013
NASONEX: Notice of Compliance 14609
Issued July 22, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14609
- Date
- July 22, 2013
- Company
- Merck Canada IncKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To include in the 'clinical trials' section of the PM information related to previously reviewed clinical studies pertaining to both the seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) indications
- Therapeutic class
- Corticosteroid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NASONEX | Not yet assigned | — |
Medicinal ingredients
- MOMETASONE FUROATE MONOHYDRATE 50 MCG per SPR